FDA Expands Casgevy Gene Therapy Approval to Children as Young as 2 with Sickle Cell Disease
First CRISPR-based gene therapy approved for young children with sickle cell disease
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Casgevy (exagamglogene autotemcel), allowing its use in children as young as 2 years old with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT).
The decision marks the first gene therapy approved for children ages 2 and older with sickle cell disease, significantly expanding access to one of the most advanced treatments currently available for these inherited blood disorders.
Casgevy was previously approved in 2023 for patients 12 years of age and older.
How Casgevy Works
Casgevy is a one-time, personalized gene therapy that uses the patient’s own blood-forming stem cells.
The treatment employs CRISPR/Cas9 gene-editing technology to modify the patient’s DNA outside the body. After the edited stem cells are infused back into the patient, they produce increased levels of fetal hemoglobin (HbF), which prevents red blood cells from developing the abnormal sickle shape responsible for painful vaso-occlusive crises.
For patients with transfusion-dependent beta thalassemia, increased fetal hemoglobin production can eliminate the need for ongoing blood transfusions.
Before receiving the therapy, patients undergo myeloablative conditioning, an intensive chemotherapy regimen that prepares the bone marrow to receive the modified stem cells.
Clinical Results
Sickle Cell Disease
Among pediatric patients aged 5 to under 12 years, 8 of 8 evaluable patients (100%) experienced no severe vaso-occlusive crises for at least 12 consecutive months within the first two years after treatment.
Beta Thalassemia
Among pediatric patients, 8 of 9 evaluable patients achieved transfusion independence for at least 12 consecutive months, and median duration of transfusion independence was 20.1 months.
FDA extended the indication to children 2 years and older based on these clinical data together with scientific evidence supporting use in younger patients.
Safety Profile
The most common adverse reactions included mucositis, febrile neutropenia, and decreased appetite.
The prescribing information also includes warnings regarding neutrophil engraftment failure, delayed platelet recovery, hypersensitivity reactions, and potential off-target CRISPR genome editing.
Expedited FDA Review
The supplemental application was approved just 53 days after filing through the FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program, making it the eighth product approved under the initiative.
Casgevy also received orphan drug designation, regenerative medicine advanced therapy (RMAT) designation, and fast track designation.
The therapy is manufactured by Vertex Pharmaceuticals.
Why It Matters
Sickle cell disease and transfusion-dependent beta thalassemia are lifelong genetic disorders that often begin causing irreversible organ damage during childhood.
By extending approval to children as young as two years old, FDA is making curative-intent gene therapy available much earlier in the disease process, when preventing long-term complications may have the greatest impact.
The approval also represents another milestone in the clinical application of CRISPR gene editing, moving genome editing beyond experimental medicine and into earlier intervention for inherited diseases.
Regulatory Insight
Gene Editing Is Entering a New Regulatory Era
Casgevy’s expanded approval reflects more than a pediatric indication. It demonstrates how FDA is becoming increasingly comfortable regulating gene-editing therapies as evidence accumulates.
When Casgevy was first approved, it marked the world’s first FDA-approved CRISPR-based therapy. This latest decision extends that confidence to much younger patients, recognizing that treating inherited diseases earlier may prevent irreversible organ damage before it occurs.
The approval also highlights FDA’s evolving use of scientific extrapolation. Rather than requiring large clinical trials in every pediatric age group, the agency combined strong clinical results in older children with established knowledge of the disease and product biology to support approval for patients as young as two years of age.
Finally, the review itself demonstrates FDA’s growing emphasis on accelerating therapies for serious conditions. Casgevy received approval just 53 days after filing through the Commissioner’s National Priority Voucher (CNPV) Pilot Program while also benefiting from Fast Track, RMAT, and Orphan Drug designations.
Regulatory Lesson
Modern biologics regulation is increasingly focused on delivering transformative therapies to patients sooner—not by lowering evidentiary standards, but by combining expedited review pathways, advanced science, and risk-based regulatory decision-making.
Class I Recall for Bolton Medical RelayPro Thoracic Stent Graft
FDA Issues Class I Recall for RelayPro Thoracic Stent Graft Following Three Patient DeathsDeployment failure during aortic repair may require emergency open surgery The U.S. Food and Drug Administration (FDA) has issued a Class I recall for certain RelayPro Thoracic...
FDA Issues Early Alert for Resmed Astral Ventilators
Resmed VentilatorPatients should continue using devices unless instructed otherwise by their healthcare provider The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain Resmed Astral 100 and...
One Contaminated Alcohol Pad, Multiple Recalls
A Lesson in Medical Device Supply Chain Quality At first glance, Cardinal Health's recent recall of Webcol™ Alcohol Prep Pads appears straightforward. A commonly used healthcare product was found to be contaminated with Paenibacillus phoenicis, creating a potential...
Early Alert: Windstone Medical Recall for Convenience Kits
FDA Warns of Convenience Kits Containing Recalled Cardinal Health Alcohol Pads The FDA has issued an Early Alert regarding several medical convenience kits distributed by Windstone Medical Packaging, Inc. that contain alcohol prep pads previously recalled by Cardinal...
Webcol Alcohol Prep Pads Recall Due to Microbial Contamination
Cardinal Health Recalls Alcohol Prep Pads Over Infection Risk Concerns Cardinal Health has issued a voluntary nationwide recall of select lots of its Webcol™ Large Alcohol Prep Pads (70% isopropyl alcohol) after testing identified microbial contamination with...
FDA Issues Warning Letter for Modifications to Infant Products
FDA Issues Warning Letter to Happiest Baby Over SNOO Smart Sleeper Modifications and Quality System Deficiencies The U.S. Food and Drug Administration has issued a Warning Letter to Happiest Baby, Inc., manufacturer of the SNOO Smart Sleeper, citing unapproved device...
